RISS 검색 - 국내학술지논문 상세보기

다국어 초록 (Multilingual Abstract)

Background: The advancement of treatment with direct-acting antiviral (DAA) agents has improved the cure rate of hepatitis C virus (HCV) infection close to 100%. The aim of our study was to assess the real-world effectiveness and safety of DAA regimens for the treatment of patients with chronic HCV genotype 2.
Methods: We retrospectively analyzed the clinical data of patients treated with sofosbuvir plus ribavirin (SOF + RBV) or glecaprevir/pibrentasvir (G/P) for chronic HCV genotype 2 infection at seven university hospitals in the Korean southeast region.
Results: SOF + RBV therapy produced an 89% and 98.3% sustained virologic response 12 week (SVR12) after treatment completion in the full analysis set and per-protocol set, respectively, and the corresponding values for G/P therapy were 89.5% and 99.2%, respectively. The difference between the treatments was probably because 6.2% (59/953) of patients in the SOF + RBV group did not complete the treatment and 9.8% (14/143) in the G/P group did not test HCV RNA after treatment completion. Adverse events (A/Es) were reported in 59.7% (569/953) and 25.9% (37/143) of the SOF + RBV and G/P groups, respectively. In the SOF + RBV group, 12 (1.26%) patients discontinued treatment owing to A/Es, whereas no patients discontinued treatment because of A/Es in the G/P group.
Conclusion: In both treatment groups, SVR was high when treatment was completed.
However, there was a high dropout rate in the SOF + RBV group, and the dropout analysis showed that these were patients with liver cirrhosis (LC; 43/285, 15.1%), especially those with decompensated LC (12/32, 37.5%). Therefore, an early initiation of antiviral therapy is recommended for a successful outcome before liver function declines. Furthermore, patients with decompensated LC who are considered candidates for SOF + RBV treatment should be carefully monitored to ensure that their treatment is completed, especially those with low hemoglobin and high alanine transaminase.

참고문헌 (Reference)

1 Wirth TC, "The impact of the revolution in hepatitis C treatment on hepatocellular carcinoma" 27 (27): 1467-1474, 2016

2 Ji F, "Sustained virologic response to direct-acting antiviral therapy in patients with chronic hepatitis C and hepatocellular carcinoma : a systematic review and meta-analysis" 71 (71): 473-485, 2019

3 Omata M, "Sofosbuvir plus ribavirin in Japanese patients with chronic genotype 2 HCV infection : an open-label, phase 3 trial" 21 (21): 762-768, 2014

4 Feld JJ, "Sofosbuvir and velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 infection" 373 (373): 2599-2607, 2015

5 Chua JV, "Sofosbuvir and velpatasvir : a stellar option for patients with decompensated hepatitis C virus(HCV)cirrhosis" 4 (4): S8-, 2016

6 Sato K, "Response-guided peginterferon-alpha-2b plus ribavirin therapy for chronic hepatitis C patients with genotype 2 and high viral loads" 42 (42): 854-863, 2012

7 Jong Eun Yeon, "Recent update of the 2017 Korean Association for the Study of the Liver (KASL) treatment guidelines of chronic hepatitis C: Comparison of guidelines from other continents, 2017 AASLD/IDSA and 2016 EASL" 대한간학회 24 (24): 278-293, 2018

8 Akahane T, "Real-world efficacy and safety of sofosbuvir + ribavirin for hepatitis C genotype 2 : a nationwide multicenter study by the Japanese Red Cross Liver Study Group" 49 (49): 264-270, 2019

9 D'Ambrosio R, "Real-world effectiveness and safety of glecaprevir/pibrentasvir in 723 patients with chronic hepatitis C" 70 (70): 379-387, 2019

10 von Wagner M, "Peginterferon-alpha2a(40KD)and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C" 129 (129): 522-527, 2005